Evotec vs Telix Pharmaceuticals
EVO and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVO and TLX compare
Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus −1.1% for Evotec).
Evotec scores higher on the StockData Score (4 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVO | TLX |
|---|---|---|
| Size and price | ||
| Share price | $1.69 | $9.72 |
| Change, 1 year | −43.5% | −3.5% |
| Change, 5 years | −92.9% | – |
| Beta (5Y) | 1.26 | 1.48 |
| Employees | 4,553 | 1,120 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −1.1% | 55.6% (better) |
| Revenue growth, 5Y average | 9.5% | – |
| Net income growth (TTM) | – | −121% |
| EPS growth (TTM) | – | −122% |
| Profitability | ||
| Gross margin | 14.5% | 53.1% (better) |
| Operating margin | −7.1% | 3.7% (better) |
| Net margin | – | −0.89% |
| FCF margin | −10.4% | −5.3% (better) |
| Return on invested capital | −7.7% | – |
| Financial health | ||
| Debt / equity | 0.10 | – |
| Net debt / EBITDA | −7.79 | 5.17 (better) |
| Interest coverage | – | 0.7× |
| Current ratio | 2.07 (better) | 2.01 |
| Piotroski F-score | – | 2 |
| Ownership | ||
| Held by institutions | 1.8% | 0.94% |
| Held by insiders | 17.1% | 8.3% |
| Insider net buying, 12 months | – | $1.0M |
Go deeper
- EVO stock overview
- EVO income statement
- EVO valuation and score
- TLX stock overview
- TLX income statement
- TLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.